GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.


Renal cell carcinoma (RCC) by Prof. David Pfister, University Hospital of Cologne, Germany

 

After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.

Prof. David Pfister has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer. 

Programme summary
Watch the video now
Other episodes of this series
Update from ASCO GU 2018

Update from ASCO GU 2018

Episode 4: Urothelial Carcinoma
Update from ASCO GU 2018

Update from ASCO GU 2018

Episode 5 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.